Literature DB >> 16837224

Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses.

Takafumi Tsuchiya1, Peter E H Schwarz, Laura Del Bosque-Plata, M Geoffrey Hayes, Christian Dina, Philippe Froguel, G Wayne Towers, Sabine Fischer, Theodora Temelkova-Kurktschiev, Hannes Rietzsch, Juergen Graessler, Josef Vcelák, Daniela Palyzová, Thomas Selisko, Bela Bendlová, Jan Schulze, Ulrich Julius, Markolf Hanefeld, Michael N Weedon, Julie C Evans, Timothy M Frayling, Andrew T Hattersley, Marju Orho-Melander, Leif Groop, Maciej T Malecki, Torben Hansen, Oluf Pedersen, Tasha E Fingerlin, Michael Boehnke, Craig L Hanis, Nancy J Cox, Graeme I Bell.   

Abstract

We conducted pooled and meta-analyses of the association of the calpain-10 gene (CAPN10) polymorphisms SNP-43, Indel-19 and SNP-63 individually and as haplotypes with type 2 diabetes (T2D) in 3237 patients and 2935 controls of European ancestry. In the pooled analyses, the common SNP-43*G allele was associated with modest but statistically significant increased risk of T2D (odds ratio (OR)=1.11 (95% confidence interval (CI), 1.02-1.20), P=0.01). Two haplotype combinations were associated with increased risk of T2D (1-2-1/1-2-1, OR=1.20 (1.03-1.41), P=0.02; and 1-1-2/1-2-1, OR=1.26 (1.01-1.59), P=0.04) and one with decreased risk (1-1-1/2-2-1, OR=0.86 (0.75-0.99), P=0.03). The meta-analysis also showed a significant effect of the 1-2-1/1-2-1 haplogenotype on risk (OR=1.25 (1.05-1.50), P=0.01). However, there was evidence for heterogeneity with respect to this effect (P=0.06). The heterogeneity appeared to be due to data sets in which the cases were selected from samples used in linkage studies of T2D. Using only the population-based case-control samples removed the heterogeneity (P=0.89) and strengthened the evidence for association with T2D in both the pooled (SNP-43*G, OR=1.19 (1.07-1.32), P=0.001; 1-2-1/1-2-1 haplogenotype, OR=1.46 (1.19-1.78), P=0.0003; 1-1-2/1-2-1 haplogenotype, OR=1.52 (1.12-2.06), P=0.007; and 1-1-1/2-2-1 haplogenotype, OR=0.83 (0.70-0.99), P=0.03) and the meta-analysis (SNP-43*G, OR=1.18 (1.05-1.32), P=0.005; 1-2-1/1-2-1 haplogenotype, OR=1.68 (1.33-2.11), P=0.00001). The pooled and meta-analyses as well as the linkage disequilibrium and haplotype diversity studies suggest a role for genetic variation in CAPN10 affecting risk of T2D in Europeans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837224     DOI: 10.1016/j.ymgme.2006.05.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  24 in total

1.  Association of diabetes susceptibility gene calpain-10 with pancreatic cancer among smokers.

Authors:  Pui-yee Fong; Megan D Fesinmeyer; Emily White; Federico M Farin; Sengkeo Srinouanprachanh; Zahra Afsharinejad; Margaret T Mandelson; Teresa A Brentnall; Matt J Barnett; Gary E Goodman; Melissa A Austin
Journal:  J Gastrointest Cancer       Date:  2010-09

2.  Prime suspect: the TCF7L2 gene and type 2 diabetes risk.

Authors:  Andrew T Hattersley
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 3.  Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008.

Authors:  Jose C Florez
Journal:  J Clin Endocrinol Metab       Date:  2008-09-09       Impact factor: 5.958

Review 4.  From genotype to human β cell phenotype and beyond.

Authors:  Piero Marchetti; Farooq Syed; Mara Suleiman; Marco Bugliani; Lorella Marselli
Journal:  Islets       Date:  2012-09-01       Impact factor: 2.694

5.  Functional characterisation of the bovine neuropeptide Y gene promoter and evaluation of the transcriptional activities of promoter haplotypes.

Authors:  Tanweer Alam; Bojlul Bahar; Sinéad M Waters; Mark McGee; John V O'Doherty; Torres Sweeney
Journal:  Mol Biol Rep       Date:  2011-05-12       Impact factor: 2.316

Review 6.  Pharmacogenetics of metformin response: a step in the path toward personalized medicine.

Authors:  Marc L Reitman; Eric E Schadt
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Common polymorphisms of calpain-10 and the risk of Type 2 Diabetes in a Tunisian Arab population: a case-control study.

Authors:  Intissar Ezzidi; Amira Turki; Safia Messaoudi; Molka Chaieb; Maha Kacem; Ghada M Al-Khateeb; Touhami Mahjoub; Wassim Y Almawi; Nabil Mtiraoui
Journal:  BMC Med Genet       Date:  2010-05-15       Impact factor: 2.103

Review 8.  Recent advances in the molecular genetics of type 2 diabetes mellitus.

Authors:  Antonio Brunetti; Eusebio Chiefari; Daniela Foti
Journal:  World J Diabetes       Date:  2014-04-15

Review 9.  TCF7L2 genetic defect and type 2 diabetes.

Authors:  Stéphane Cauchi; Philippe Froguel
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

10.  Calpain-10 expression is elevated in pancreatic islets from patients with type 2 diabetes.

Authors:  Charlotte Ling; Leif Groop; Silvia Del Guerra; Roberto Lupi
Journal:  PLoS One       Date:  2009-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.